Skip to main content

Table 2 Risk factors for osteoporosis and fractures, current comorbidities, and concomitant medications

From: Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS)

Characteristic

Colombia

(N = 277)

Brazil

(N = 130)

Mexico

(N = 83)

Argentina

(N = 56)

All Patients Latin America Subregion (N = 546)

Maternal history of osteoporosis or hip fracture, n (%)

57 (23.4%)

37 (40.2%)

23 (39.7%)

14 (30.4%)

131 (29.8%)

Sight problems, n (%)

133 (50.6%)

84 (68.9%)

22 (26.5%)

24 (42.9%)

263 (50.2%)

Patients experiencing falls in the past year, n (%)

103 (38.6%)

39 (31.5%)

44 (62.9%)

18 (34.0%)

204 (39.7%)

Number of falls in the past year, n (%)

No falls

164 (61.4%)

85 (68.5%)

26 (37.1%)

35 (66.0%)

310 (60.3%)

1 fall

62 (23.2%)

24 (19.4%)

14 (20.0%)

10 (18.9%)

110 (21.4%)

2 falls

21 (7.9%)

7 (5.6%)

9 (12.9%)

3 (5.7%)

40 (7.8%)

3 or more falls

20 (7.5%)

8 (6.5%)

21 (30.0%)

5 (9.4%)

54 (10.5%)

Hours of exercise per week, mean (SD)

2.6 (8.3)

1.2 (1.8)

2.1 (2.6)

2.0 (2.4)

2.1 (6.2)

Use of arms when standing up from a chair, n (%)

159 (58.2%)

74 (59.2%)

57 (68.7%)

17 (30.4%)

307 (57.2%)

Immobilized for > 12 months, n (%)

3 (1.1%)

6 (4.8%)

1 (1.2%)

1 (1.8%)

11 (2.1%)

Currently smoking, n (%)

16 (5.9%)

9 (7.0%)

10 (12.0%)

4 (7.1%)

39 (7.2%)

Alcoholic drinks per week, mean (SD)

0.2 (1.2)

0.3 (1.1)

0.2 (0.8)

0.4 (1.9)

0.2 (1.2)

Caffeinated drinks per week, mean (SD)

8.1 (9.6)

11.0 (13.6)

7.2 (6.0)

3.4 (5.0)

8.2 (10.2)

Patients with current comorbidities a, n (%)

Hypertension

124 (44.8%)

66 (51.2%)

37 (44.6%)

25 (44.6%)

252 (46.2%)

Rheumatoid arthritis or other rheumatologic conditions

81 (29.5%)

17 (13.4%)

19 (22.9%)

6 (10.9%)

123 (22.8%)

Type 2 diabetes mellitus

18 (6.5%)

18 (14.3%)

8 (9.6%)

1 (1.8%)

45 (8.3%)

Concomitant medicationsb, n (%)

Antihypertensives

83 (30.0%)

61 (46.9%)

30 (36.1%)

17 (30.4%)

191 (35.0%)

Thyroid hormones

63 (22.7%)

18 (13.8%)

18 (21.7%)

17 (30.4%)

116 (21.2%)

Antidepressants

15 (5.4%)

24 (18.5%)

1 (1.2%)

3 (5.4%)

43 (7.9%)

Insulins/oral hypoglycemics

20 (7.2%)

14 (10.8%)

5 (6.0%)

1 (1.8%)

40 (7.3%)

Glucocorticoidsc

12 (7.5%)

7 (8.0%)

0 (0.0%)

1 (2.9%)

20 (6.2%)

  1. N = total number of patients available; n = number of patients with valid (non-missing or unknown) values; SD = standard deviation
  2. aThe three most frequently reported comorbidities in the overall ALAFOS study cohort [10] are listed here
  3. bConcomitant medications related to risk of osteoporosis and falls taken by > 5% of all patients in the overall Latin American subregional cohort at baseline. Other medications included oral anticoagulants/heparin (1.3% of all patients), benzodiazepines (3.8%), antiarrhythmics (4.8%), and anticonvulsants (3.3%)
  4. cDuration of therapy ≥3 months or a prednisone daily equivalent dose ≥7.5 mg
  5. Note: Percentages are calculated using n, the number of valid (not missing or unknown) responses for each item